{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:13Z","timestamp":1790806633638,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Meningioma is the most frequent brain tumor, and the incidence is ever-increasing. Though often benign and slow growth, recurrence rates are substantial and today\u2019s surgical and radiation-based treatment are not without complications. No drugs specific for meningiomas are hitherto approved and patients with inoperable or recurrent meningioma are left with few treatment options. Somatostatin receptors are previously detected in meningiomas and may inhibit growth when stimulated by somatostatin. Hence, somatostatin analogs could provide a targeted drug therapy. The aim of this study was to compile the current insights of somatostatin analogs for patients with meningioma. This paper adheres to the PRISMA extension for Scoping Reviews. A systematic search was conducted in the search databases PubMed, Embase via Ovid, and Web of Science. Seventeen papers adhered to the inclusion and exclusion criteria, and critical appraisal was conducted. The overall quality of evidence is low, as none of the studies were randomized or controlled. Various efficacy of somatostatin analogs is reported, and adverse effects are sparse. Due to the beneficial effects reported by some studies, somatostatin analogs may offer a novel last-option treatment for severely ill-patients. Nonetheless, only a controlled study, preferably a randomized clinical trial, could clarify the efficacy of somatostatin analogs.<\/jats:p>","DOI":"10.3390\/ijms24054793","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T03:29:00Z","timestamp":1677727740000},"page":"4793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-1032","authenticated-orcid":false,"given":"Sofie Eline","family":"Tollefsen","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Solheim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway"},{"name":"Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, 7491 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mj\u00f8nes","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway"},{"name":"Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-6852","authenticated-orcid":false,"given":"Sverre Helge","family":"Torp","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway"},{"name":"Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJMoa070972","article-title":"Incidental Findings on Brain MRI in the General Population","volume":"357","author":"Vernooij","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/noab132","article-title":"An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression during Active Surveillance or after Stereotactic Radiosurgery: The IMPASSE Study","volume":"24","author":"Sheehan","year":"2022","journal-title":"Neuro. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An Overview of Meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_6","first-page":"283","article-title":"Chapter 7: Meningioma","volume":"Volume 6","author":"Louis","year":"2021","journal-title":"WHO Classificaton of Tumours Editorial Board: Central Nervous System Tumours"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO Guideline on the Diagnosis and Management of Meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"579599","DOI":"10.3389\/fonc.2020.579599","article-title":"Meningioma: A Review of Clinicopathological and Molecular Aspects","volume":"10","author":"Huntoon","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","article-title":"Meningiomas: Knowledge Base, Treatment Outcomes, and Uncertainties. A RANO Review","volume":"122","author":"Rogers","year":"2015","journal-title":"J. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3389\/fonc.2020.01523","article-title":"An Overview of Managements in Meningiomas","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_11","first-page":"V07180489","article-title":"Intrakraniale meningeomer","volume":"181","author":"Andersen","year":"2019","journal-title":"Ugeskr. Laeger."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.21037\/cco.2017.05.02","article-title":"Classification of Meningiomas-Advances and Controversies","volume":"6","author":"Harter","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fneur.2020.00373","article-title":"A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and\/or Refractory Meningiomas","volume":"11","author":"Hrachova","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.dld.2003.11.007","article-title":"Somatostatin Receptors and Regulation of Cell Proliferation","volume":"36","author":"Bousquet","year":"2004","journal-title":"Dig. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and Its Receptor Family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin Receptors: From Signaling to Clinical Practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0024-3205(95)02082-T","article-title":"The Somatostatin Receptor Family","volume":"57","author":"Patel","year":"1995","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0928-4257(00)00206-0","article-title":"Signal Transduction of Somatostatin Receptors Negatively Controlling Cell Proliferation","volume":"94","author":"Ferjoux","year":"2000","journal-title":"J. Physiol. Paris"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0002-9440(10)65564-2","article-title":"Immunohistochemical Localization of Somatostatin Receptors Sst2A in Human Tumors","volume":"153","author":"Reubi","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_20","first-page":"13185","article-title":"Expression of Somatostatin Receptors (SSTR1-SSTR5) in Meningiomas and Its Clinicopathological Significance","volume":"8","author":"Ongaratti","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tollefsen, S.E., Jarmund, A.H., Ytterhus, B., Salvesen, \u00d8., Mj\u00f8nes, P., and Torp, S.H. (2021). Somatostatin Receptors in Human Meningiomas\u2014Clinicopathological Aspects. Cancers, 13.","DOI":"10.3390\/cancers13225704"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and Somatostatin Analogues: Pharmacokinetics and Pharmacodynamic Effects","volume":"35","author":"Harris","year":"1994","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/EJE-19-0074","article-title":"ANNIVERSARY REVIEW: Octreotide, 40 Years Later","volume":"181","author":"Lamberts","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO Guidelines for the Diagnosis and Treatment of Meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_25","unstructured":"(2023, February 24). Helsedirektoratet Nasjonalt Handlingsprogram Med Retningslinjer for Diagnostikk, Behandling og Oppf\u00f8lging av Meningeomer. Available online: https:\/\/www.helsedirektoratet.no\/retningslinjer\/meningeomer-handlingsprogram."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_27","unstructured":"(2021, May 06). Joanna Briggs Institute Critical-Appraisal-Tools-Critical Appraisal Tools, Joanna Briggs Institute. Available online: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000448212","article-title":"Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues","volume":"9","year":"2016","journal-title":"Case Rep. Oncol."},{"key":"ref_29","first-page":"237","article-title":"Clinical Use of Octreotide in Unresectable Meningiomas. A Report of Three Cases","volume":"37","author":"Relimpio","year":"1993","journal-title":"J. Neurosurg. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0303-8467(97)00110-8","article-title":"Visual Improvement during Octreotide Therapy in a Case of Episellar Meningioma","volume":"100","author":"Minniti","year":"1998","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3171\/2015.1.JNS142260","article-title":"Anaplastic Meningioma: Octreotide Therapy for a Case of Recurrent and Progressive Intracranial Disease","volume":"124","author":"Rammo","year":"2016","journal-title":"J. Neurosurg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.clineuro.2012.07.021","article-title":"Multifocal CNS Demyelination after Octreotide Treatment for Metastatic Meningioma","volume":"115","author":"Schreglmann","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cardona, A.F., Ruiz-Pati\u00f1o, A., Zatarain-Barr\u00f3n, Z.L., Hakim, F., Jim\u00e9nez, E., Mej\u00eda, J.A., Ram\u00f3n, J.F., Useche, N., Berm\u00fadez, S., and Pineda, D. (2019). Systemic Management of Malignant Meningiomas: A Comparative Survival and Molecular Marker Analysis between Octreotide in Combination with Everolimus and Sunitinib. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217340"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/nov183","article-title":"Kinetics of Tumor Size and Peritumoral Brain Edema before, during, and after Systemic Therapy in Recurrent WHO Grade II or III Meningioma","volume":"18","author":"Furtner","year":"2016","journal-title":"Neuro. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-021-03741-7","article-title":"Multimodal Management of Surgery- and Radiation-Refractory Meningiomas: An Analysis of the French National Tumor Board Meeting on Meningiomas Cohort","volume":"153","author":"Graillon","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_36","first-page":"526","article-title":"Recurrent Meningioma: Salvage Therapy with Long-Acting Somatostatin Analogue","volume":"9","author":"Chamberlain","year":"2007","journal-title":"Neuro-Oncology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II Study of Subcutaneous Octreotide in Adults with Recurrent or Progressive Meningioma and Meningeal Hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II Study of Monthly Pasireotide LAR (SOM230C) for Recurrent or Progressive Meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","article-title":"Recurrent High-Grade Meningioma: A Phase II Trial with Somatostatin Analogue Therapy","volume":"73","author":"Argyriou","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined Treatment by Octreotide and Everolimus: Octreotide Enhances Inhibitory Effect of Everolimus in Aggressive Meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55361","DOI":"10.18632\/oncotarget.19517","article-title":"Pasireotide Is More Effective than Octreotide, Alone or Combined with Everolimus on Human Meningioma in vitro","volume":"8","author":"Graillon","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3171\/2016.8.JNS16995","article-title":"Octreotide Therapy in Meningiomas: In Vitro Study, Clinical Correlation, and Literature Review","volume":"127","author":"Graillon","year":"2017","journal-title":"J. Neurosurg."},{"key":"ref_44","first-page":"543","article-title":"Somatostatin Inhibits the Activity of Adenylate Cyclase in Cultured Human Meningioma Cells and Stimulates Their Growth","volume":"74","author":"Koper","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0950-351X(96)80362-4","article-title":"Somatostatin Receptors and Disease: Role of Receptor Subtypes","volume":"10","author":"Hofland","year":"1996","journal-title":"Bailliere\u2019s Clin. Endocrinol. Metab."},{"key":"ref_46","unstructured":"(2021, May 07). PubChem Lanreotide, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6918011."},{"key":"ref_47","first-page":"1865","article-title":"Immunohistochemical Determination of Five Somatostatin Receptors in Meningioma Reveals Frequent Overexpression of Somatostatin Receptor Subtype Sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of Somatostatin Receptor MRNA in Human Meningiomas and Their Implication in in Vitro Antiproliferative Activity","volume":"66","author":"Arena","year":"2004","journal-title":"J. Neurooncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical Benchmarks for Medical Therapy Trials in Surgery- and Radiation-Refractory Meningioma: A RANO Review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1634\/theoncologist.2015-0420","article-title":"Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature","volume":"21","author":"Faggiano","year":"2016","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The Tor Pathway: A Target for Cancer Therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","unstructured":"U.S. Food and Drug Administration Everolimus (Afinitor) (2023, February 24). FDA, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/everolimus-afinitor."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-14-0249","article-title":"Preoperative Octreotide Treatment of Acromegaly: Long-Term Results of a Randomised Controlled Trial","volume":"171","author":"Fougner","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Filippi, L., Palumbo, I., Bagni, O., Schillaci, O., Aristei, C., and Palumbo, B. (2022). Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071666"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas","volume":"56","author":"Forrer","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Fodi, C.-K., Schittenhelm, J., Honegger, J., Castaneda-Vega, S.G., and Behling, F. (2022). The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092364"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-Analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin Receptor Theranostics for Refractory Meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_61","first-page":"1538","article-title":"Somatostatin Receptor-Targeted Radionuclide Therapy for Progressive Meningioma: Benefit Linked to 68Ga-DOTATATE\/-TOC Uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10143-022-01849-6","article-title":"Somatostatin Analogues in Treatment-Refractory Meningioma: A Systematic Review with Meta-Analysis of Individual Patient Data","volume":"45","author":"Jensen","year":"2022","journal-title":"Neurosurg. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:45:39Z","timestamp":1760121939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24054793"],"URL":"https:\/\/doi.org\/10.3390\/ijms24054793","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}